Get started
Author

Junine Toy

Observed names: J Toy, K. Junine Toy, Toy, Junine
ORCID: 0000-0001-8803-3744
Observed ORCID: 0000-0001-8803-3744
OpenAlex ID: A5049617747
Emergent drug resistance with integrase strand transfer inhibitor-based regimens
2017 · Katherine J. Lepik, P. Richard Harrigan, et al. · AIDS · 103
Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy
2022 · Zabrina L. Brumme, Francis Mwimanzi, et al. · npj Vaccines · 95
PDF
People With Human Immunodeficiency Virus Receiving Suppressive Antiretroviral Therapy Show Typical Antibody Durability After Dual Coronavirus Disease 2019 Vaccination and Strong Third Dose Responses
2022 · Hope R Lapointe, Francis Mwimanzi, et al. · The Journal of Infectious Diseases · 54
PDF
Adverse drug reactions to integrase strand transfer inhibitors
2018 · Katherine J. Lepik, Benita Yip, et al. · AIDS · 49
Antibody response durability following three-dose coronavirus disease 2019 vaccination in people with HIV receiving suppressive antiretroviral therapy
2022 · Hope R. Lapointe, Francis Mwimanzi, et al. · AIDS · 21
Impact of SARS-CoV-2 lockdown on expansion of HIV transmission clusters among key populations: A retrospective phylogenetic analysis
2022 · Rachel L. Miller, Angela McLaughlin, et al. · The Lancet Regional Health - Americas · 20
HIV antiviral drug resistance: patient comprehension
2010 · C. Sarai Racey, Wendy Zhang, et al. · AIDS Care · 18
Longitudinal evolution of the HIV effective reproduction number following sequential expansion of treatment as prevention and pre-exposure prophylaxis in British Columbia, Canada: a population-level programme evaluation
2024 · Viviane D Lima, Jielin Zhu, et al. · The Lancet HIV · 12
Identification of people with low prevalence diseases in administrative healthcare records: A case study of HIV in British Columbia, Canada
2023 · Scott D. Emerson, Taylor McLinden, et al. · PLoS ONE · 11
PDF
Prevalence and incidence of hepatitis C infection amongst men who have sex with men in a population‐based pre‐exposure prophylaxis program in British Columbia, Canada
2022 · Kyle A. Thompson, Gabriel Blank, et al. · Liver International · 11
Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with Aspergillus pneumonia
2011 · Junine Toy, Pierre Giguère, et al. · AIDS · 10
The impact of the COVID-19 pandemic on HIV treatment gap lengths and viremia among people living with HIV British Columbia, Canada, during the COVID-19 pandemic: Are we ready for the next pandemic?
2024 · Lalani L. Munasinghe, Weijia Yin, et al. · Social Science & Medicine · 9
Doxycycline postexposure prophylaxis to prevent bacterial sexually transmitted infections
2025 · Victor Leung, Junine Toy, et al. · Canadian Medical Association Journal · 6
PDF
Risk Factors, Screening, Diagnosis, and Treatment of Osteoporosis in HIV-Infected Adults in an HIV Primary Care Clinic
2022 · Kevin Kwok, Caitlin Olatunbosun, et al. · The Canadian Journal of Hospital Pharmacy · 6
PDF
Evolving patterns of antiretroviral drug interactions in people with HIV in British Columbia, Canada
2022 · Katherine J. Lepik, Lu Wang, et al. · AIDS · 5
Post-Marketing Experience with Nevirapine Extended Release (XR) Tablets: Effectiveness and Tolerability in a Population-Based Cohort in British Columbia, Canada
2014 · Katherine J Lepik, Benita Yip, et al. · Antiviral Therapy · 5
Generalized Treatment as Prevention Plus Focused Pre-Exposure Prophylaxis Is the Key to Controlling HIV/AIDS
2025 · Julio S. G. Montaner, Viviane D. Lima, et al. · Tropical Medicine and Infectious Disease · 4
Chronic Hepatitis B Infection Among Preexposure Prophylaxis Users Enrolled in a Population-Based Program in British Columbia, Canada
2021 · Kyle A Thompson, Gabriel Blank, et al. · Open Forum Infectious Diseases · 4
PDF
Adverse drug reactions attributed to generic substitution of antiretroviral medications among HIV treatment and pre-exposure prophylaxis clients in British Columbia, Canada
2024 · Katherine J Lepik, Olivia L Hunt, et al. · Antiviral Therapy · 3
Process description of developing HIV prevention monitoring indicators for a province-wide pre-exposure prophylaxis (PrEP) program in British Columbia, Canada
2023 · Lalani L. Munasinghe, Junine Toy, et al. · PLoS ONE · 3
PDF
Untimed Efavirenz Drug Levels After Switching From Brand to Generic Formulations: A Short Communication
2021 · Birgit E. Watson, Kieran Atkinson, et al. · Therapeutic Drug Monitoring · 3
Examining the secondary impacts of the COVID-19 pandemic on syndemic production and PrEP use among gay, bisexual and other men who have sex with men (GBM) in Vancouver, Canada
2023 · Jordan M. Sang, David M. Moore, et al. · BMC Public Health · 2
PDF
Evaluation of Treatment Tolerability, Satisfaction and Laboratory Parameters in HIV+ Patients Switching from Ritonavir Capsule to Tablet Formulation§
2013 · Andy Mtambo, Marianne Harris, et al. · Current HIV Research · 2
Rapid rebound in hepatitis B DNA in previously undetectable hepatitis B/HIV co-infected patients switching from tenofovir to entecavir therapy
2008 · M Hull, J Toy, et al. · Journal of the International AIDS Society · 2
PDF
Heterogeneous impacts of HIV pre-exposure prophylaxis (PrEP) on drug resistance and phylogenetic cluster transmission dynamics in British Columbia, Canada: A retrospective cohort and simulation study
2025 · Angela McLaughlin, K. Junine Toy, et al. · PLoS Medicine · 1
Works count: 35
Citation count: 459
H-index: 10
I10-index: 11
Year
Topic
Type